Alan Bash is joining Legend Biotech as its president of Carvykti, an unconventional, newly-created role to oversee the ...

The pharmaceutical company says data on 10 deaths and more than 100 hospitalizations comes from the FDA’s adverse event reporting database for semaglutide — the key ingredient in Ozempic and Wegovy, ...

Nearly $3.8 billion was earned by Novo Nordisk A/S and Eli Lilly and Co. in the third quarter for their glucagon-like peptide ...

The head of the company that makes the diabetes and obesity drugs Ozempic and Wegovy has warned that compounded versions of ...

Novo Nordisk stock inched down Wednesday after the drugmaker's weight-loss drug beat forecasts, but sales of its diabetes behemoth missed.

Novo Nordisk (NVO) teased some new details about a potential Ozempic successor during a call with investors Tuesday.

Novo Nordisk on Wednesday nudged higher its outlook for the year as the drugmaker registered another quarter of strong sales of its weight-loss drugs.

Novo Nordisk (NVO), the maker of blockbuster weight-loss and diabetes drugs Wegovy and Ozempic, has entered an agreement with Denmark-based Ascendis Pharma (ASND) to leverage the latter’s advanced ...